The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease

European Journal of Internal Medicine

Volumn 19, Issue 2, 2008, Pages 104-108

  Karadag, Fisun ^a   Kirdar, Sevin ^a   Karul, Aslihan B ^a   Ceylan, Emel ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Interleukin 6; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; LUNG FUNCTION; MALE; MALNUTRITION; TURBIDIMETRY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MALNUTRITION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39049147868     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.04.026     Document Type: Article

References (38)

1. National Heart, Lung, and Blood Institute. Morbidity & mortality: chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998. Available from: URL: www.nhlbi.nih.gov/nhlbi/seiin/other/cht-book/htm
2. Murray C.J.L., and Lopez A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274 (1996) 740-743
3. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
4. Anthonisen N.R., Connett J.E., Enright P.L., and Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166 (2002) 333-339
5. Schols A.M., Buurman W.A., Staal van den Brekel A.J., Dentener M.A., and Wouters E.F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (1996) 819-824
6. De Godoy I., Donahoe M., Calhoun W.J., Mancino J., and Rogers R.M. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153 (1996) 633-637
7. De Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 27 (2006) 902-907
8. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004) 574-580
9. Schneider A., Dinant G.J., Maag I., Gantner L., Meyer J.F., and Szecsenyi J. The added value of C-reactive protein to clinical signs and symptoms in patients with obstructive airway disease: results of a diagnostic study in primary care. BMC Fam Pract 7 (2006) 28
10. Pepys M.B. C-reactive protein fifty years on. Lancet 1 (1981) 653-657
11. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
12. Tracey K.J., and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45 (1994) 491-503
13. Vernooy J.H., Kucukaycan M., Jacobs J.A., Chavannes N.H., Buurman W.A., Dentener M.A., et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 1218-1224
14. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease (Updated 2006). Available from URL: http://www.goldcopd.com/
15. ATS/ERS Task Force. Standardization of lung function testing. Eur Respir J 26 (2005) 319-338
16. Otsuji S., Shibata H., and Umeda M. Turbidimetric immunassay of serum C-reactive protein. Clin Chem 28 (1982) 2121-2124
17. Aukrust P., Müller F., Lien E., Nordoy I., Liabakk N., Kvale D., et al. Tumor necrosis factor (tnf) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infec Dis 179 (1999) 74-82
18. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429 (2001) 195-207
19. Wouters E.F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 57 (2002) 1067-1070
20. Langen R.C., Korn S.H., and Wouters E.F. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 35 (2003) 226-235
21. Mukae H., Hogg J.C., English D., Vincent R., and van Eeden S.F. Phagocytosis of particulate air pollutants by human alveolar macrophages stimulates the bone marrow. Am J Physiol Lung Cell Mol Physiol 279 (2000) L924-L931
22. Gan W.Q., Man S.F., and Sin D.D. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127 (2005) 558-564
23. Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., and Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61 (2006) 849-853
24. Dev D., Wallace E., Sankaran R., Cunniffe J., Govan J.R., Wathen C.G., and Emmanuel F.X. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 92 (1998) 664-667
25. Hurst J.R., Donaldson G.C., Perera W.R., Wilkinson T.M., Bilello J.A., Hagan G.W., Vessey R.S., and Wedzicha J.A. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 (2006) 867-874
26. Van Helvoort H.A., Heijdra Y.F., Thijs H.M., Vina J., Wanten G.J., and Dekhuijzen P.N. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 38 (2006) 1543-1552
27. Man S.F., and Sin D.D. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 78-82
28. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
29. Broekhuizen R., Wouters E.F., Creutzberg E.C., and Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 (2006) 17-22
30. Eid A.A., Jonescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., and Shale D.J. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 1414-1418
31. Takabatake N., Nakamura H., Abe S., Hino T., Saito H., Yuki H., Kato S., and Tomoike H. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 (1999) 1215-1219
32. Tracey K.J., and Cerami A. Metabolic responses to cachectin/TNF. A brief review. Ann N Y Acad Sci 587 (1990) 325-331
33. Di Francia M., Barbier D., Mege J.L., and Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150 (1994) 1453-1455
34. Takabatake N., Nakamura H., Abe S., Inoue S., Hino T., et al. The relationship between chronic hypoxemia and activation of tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 1179-1184
35. Cirillo D.J., Agrawal Y., and Cassano P.A. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 155 (2002) 842-848
36. Dentener M.A., Creutzberg E.C., Schols A.M., Mantovani A., van't Veer C., Burman W.A., and Wouters E.F. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1receptor II during treatment of exacerbations. Thorax 56 (2001) 721-726
37. Keatings V.M., Collins P.D., Scott D.M., and Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153 (1996) 530-534
38. Pinto-Plata V.M., Mullerova H., Toso J.F., Feudjo-Tepie M., Soriano J.B., Vessey R.S., and Celli B.R. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61 (2006) 23-28